MA53976A - Anticorps de chimiokine pan-elr + cxc pour le traitement de l'hidradénite suppurativa - Google Patents

Anticorps de chimiokine pan-elr + cxc pour le traitement de l'hidradénite suppurativa

Info

Publication number
MA53976A
MA53976A MA053976A MA53976A MA53976A MA 53976 A MA53976 A MA 53976A MA 053976 A MA053976 A MA 053976A MA 53976 A MA53976 A MA 53976A MA 53976 A MA53976 A MA 53976A
Authority
MA
Morocco
Prior art keywords
elr
pan
treatment
cxc chemokine
hidradenitis suppurativa
Prior art date
Application number
MA053976A
Other languages
English (en)
Inventor
Kristine Kay Kikly
Dipak Ratilal Patel
Derrick Ryan Witcher
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA53976A publication Critical patent/MA53976A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA053976A 2018-10-22 2019-10-15 Anticorps de chimiokine pan-elr + cxc pour le traitement de l'hidradénite suppurativa MA53976A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862748838P 2018-10-22 2018-10-22
US201962791061P 2019-01-11 2019-01-11

Publications (1)

Publication Number Publication Date
MA53976A true MA53976A (fr) 2022-01-26

Family

ID=68425364

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053976A MA53976A (fr) 2018-10-22 2019-10-15 Anticorps de chimiokine pan-elr + cxc pour le traitement de l'hidradénite suppurativa

Country Status (16)

Country Link
US (1) US12037387B2 (fr)
EP (1) EP3870288A1 (fr)
JP (2) JP7171913B2 (fr)
KR (2) KR20240014601A (fr)
CN (1) CN112912140B (fr)
AU (1) AU2019364239B2 (fr)
BR (2) BR112021004900A2 (fr)
CA (1) CA3117142A1 (fr)
IL (1) IL282307A (fr)
MA (1) MA53976A (fr)
MX (1) MX2021004363A (fr)
MY (1) MY197879A (fr)
SG (1) SG11202102904TA (fr)
TW (1) TWI737000B (fr)
UA (1) UA128649C2 (fr)
WO (1) WO2020086327A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202206457A (zh) * 2020-04-24 2022-02-16 美商美國禮來大藥廠 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012014080A (es) * 2010-06-03 2013-05-01 Abbvie Biotechnology Ltd Usos y composiciones para el tratamiento de hidradenitis superativa (hs).
TWI612059B (zh) * 2013-03-15 2018-01-21 美國禮來大藥廠 泛－ＥＬＲ<sup>＋</sup>ＣＸＣ趨化因子抗體
US9290570B2 (en) * 2013-03-15 2016-03-22 Eli Lilly And Company Pan-ELR+ CXC Chemokine Antibodies
KR101418306B1 (ko) 2013-03-19 2014-07-15 김대운 바지의 흘러내림 방지용 버팀기둥
WO2015197098A1 (fr) * 2014-06-26 2015-12-30 Xigen Inflammation Ltd. Nouvelle utilisation d'inhibiteurs peptidiques perméables aux cellules de la voie de transduction du signal jnk pour le traitement de diverses maladies
WO2016098071A1 (fr) * 2014-12-18 2016-06-23 Csir Immunomodulation par contrôle des taux de chimiokines pro-inflammatoires elr+ au moyen du long arn non codant umlilo
CA3053231A1 (fr) * 2017-02-16 2018-08-23 Xbiotech Inc. Traitement de l'hidradenite suppurative

Also Published As

Publication number Publication date
KR102628314B1 (ko) 2024-01-25
CN112912140A (zh) 2021-06-04
TWI737000B (zh) 2021-08-21
US20210340244A1 (en) 2021-11-04
CN112912140B (zh) 2024-08-20
WO2020086327A1 (fr) 2020-04-30
JP2023011819A (ja) 2023-01-24
UA128649C2 (uk) 2024-09-18
JP7410256B2 (ja) 2024-01-09
EP3870288A1 (fr) 2021-09-01
MX2021004363A (es) 2021-05-31
US12037387B2 (en) 2024-07-16
BR112021004900A2 (pt) 2021-06-01
KR20240014601A (ko) 2024-02-01
JP7171913B2 (ja) 2022-11-15
TW202028233A (zh) 2020-08-01
CA3117142A1 (fr) 2020-04-30
KR20210060582A (ko) 2021-05-26
SG11202102904TA (en) 2021-05-28
AU2019364239A1 (en) 2021-04-22
IL282307A (en) 2021-05-31
JP2022512721A (ja) 2022-02-07
BR122023023399A2 (pt) 2024-02-20
AU2019364239B2 (en) 2023-02-02
MY197879A (en) 2023-07-22

Similar Documents

Publication Publication Date Title
MA49767A (fr) Conjugués de cytokine pour le traitement de maladies auto-immunes
MA52232A (fr) Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d&#39;utilisation pour le traitement du cancer
MA43982A (fr) Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1
MA45481A (fr) Utilisation d&#39;exosomes pour le traitement de maladies
MA51739A (fr) Compositions pharmaceutiques pour le traitement de la fibrose kystique
MA52575A (fr) Pansement pour le traitement de la peau endommagée
MA52631A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
MA50406B1 (fr) Inhibiteurs pyrazole de magl
MA52861A (fr) Méthodes et compositions pour le traitement de l&#39;apnée du sommeil
MA43825A (fr) Schémas posologiques pour le traitement d&#39;infections fongiques
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA47362A (fr) Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
MA49576A (fr) Compositions et méthodes pour le traitement d&#39;infections fongiques
MA53609A (fr) Polynucléotides codant la glucose-6-phosphatase pour le traitement de la glycogénose
MA49131A (fr) Utilisation d&#39;antagonistes de klk5 pour le traitement d&#39;une maladie
MA55490A (fr) Mutéine de lipocaline pour le traitement de l&#39;asthme
MA55872A (fr) Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires
MA55148A (fr) Composés d&#39;aryl-aniline et d&#39;hétéroaryl-aniline pour le traitement de marques de naissance
MA53370A (fr) Procédé et intermédiaires pour la préparation de bilastine
MA51795A (fr) Oligonucléotides pour moduler l&#39;expression de tmem106b
MA45552A (fr) Compositions destinées au traitement de l&#39;amylose
MA55973A (fr) Composé pour le traitement de la goutte ou de l&#39;hyperuricémie
MA53252A (fr) Thérapie génique non perturbatrice pour le traitement d&#39;un mma
MA54792A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
MA41629A (fr) Compositions et méthodes d&#39;utilisation de l&#39;hormone anti-müllérienne pour le traitement de l&#39;infertilité